{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/adverse-drug-reactions/background-information/categorization-of-adrs/","result":{"pageContext":{"chapter":{"id":"68cfd9ca-f6d9-582b-a898-39bd0927455f","slug":"categorization-of-adrs","fullItemName":"Categorization of ADRs","depth":2,"htmlHeader":"<!-- begin field a076dfec-b782-4171-81b9-8b9fb41cbab8 --><h2>How are adverse drug reactions categorized?</h2><!-- end field a076dfec-b782-4171-81b9-8b9fb41cbab8 -->","summary":"","htmlStringContent":"<!-- begin item 27c426eb-7cca-4a6f-afcf-46869ab2d51f --><!-- begin field d6b8f129-5ca4-4aa3-ae3a-c968601e8ffa --><ul><li><strong>Adverse drug reactions (ADRs) are frequently categorized as Type A or Type B</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">Rawlins and Thompson, 1977</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">Pirmohamed et al, 1998</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">Edwards and Aronson, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">MCA and CSM, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">MHRA, 2015a</a>]<strong>:</strong><ul><li><strong>Type A reactions </strong>(pharmacological/augmented reactions) result from an exaggeration of a drug’s normal pharmacological actions when given at the usual therapeutic dose (for example respiratory depression with opioids or bleeding with warfarin). They are dose dependent and are therefore readily reversible on reducing the dose of (or withdrawing treatment with) the drug. Type A reactions also include those that are not directly related to the desired pharmacological action of the drug (for example, dry mouth with tricyclic antidepressants).</li><li><strong>Type B reactions </strong>(idiosyncratic/bizarre reactions) cannot be predicted from the known pharmacology of the drug (for example, anaphylaxis with penicillin and skin rashes with antibiotics).</li><li>Type A adverse reactions are more common than Type B reactions and account for more than 80% of all reactions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">Pirmohamed et al, 1998</a>]. Type B reactions may only be discovered for the first time after a drug has already been made available for general use.<strong> </strong></li></ul></li><li><strong>Other categories of ADRs include </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">MHRA, 2015a</a>]<strong>:</strong><ul><li>Type C reactions (continuing reactions) — these persist for a relatively long time (for example, osteonecrosis of the jaw with bisphosphonates).</li><li>Type D reactions (delayed reactions) — these become apparent some time after the use of a drug, thereby making them more difficult to detect (for example, leucopoenia occurring up to six weeks following some chemotherapeutic drugs, for example, lomustine).</li><li>Type E reactions (end-of-use reactions) — these are associated with the withdrawal of a drug (for example, insomnia, anxiety, and perceptual disturbances following the withdrawal of benzodiazepines).</li></ul></li><li><strong>Other classifications have been proposed to take into account properties of the reaction, the person, and other biological differences.</strong><ul><li>For example, the DoTS system takes into account the dose-relatedness of the reaction, timing of the reaction, and individual susceptibility to the drug [<a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">Aronson and Ferner, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">Aronson and Ferner, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">Aronson, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/adverse-drug-reactions/references/\">MHRA, 2015a</a>].</li></ul></li></ul><!-- end field d6b8f129-5ca4-4aa3-ae3a-c968601e8ffa --><!-- end item 27c426eb-7cca-4a6f-afcf-46869ab2d51f -->","topic":{"id":"5891f47f-d14e-5ade-b43e-09ab2ee894c3","topicId":"fb7af4be-ae9d-4213-b2ca-ca17ddb868c1","topicName":"Adverse drug reactions","slug":"adverse-drug-reactions","lastRevised":"Last revised in March 2017","chapters":[{"id":"78737b02-a5d5-5686-924f-3bd67a984373","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3124c32f-664e-57ef-805a-95067102ad32","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"23e3d730-4bbb-5a3a-bd97-77a17bee3f53","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0974ec45-5b01-515b-b02e-5cad23aacea1","slug":"changes","fullItemName":"Changes"},{"id":"6474141f-1642-5857-9d25-033f3b7503f0","slug":"update","fullItemName":"Update"}]},{"id":"5bad1097-961b-5653-8f9b-6456f05b7836","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"6be883ff-72cf-54e9-b064-31f4df584e67","slug":"goals","fullItemName":"Goals"},{"id":"c6cc81cc-134f-5d98-b79c-967bf65bddd3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"95dab13c-419c-5de3-b7fd-95118f8b48e5","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d675aba3-9d84-5b1a-9c2b-79cc7bcab6c3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd63cb73-82b3-5c83-bea6-b82fa98f7888","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"977ca222-407c-5643-a723-eeee2b2f6c0f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b68bacaa-d4b5-58a7-b9d6-46bf7c82f8ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"26252f90-7908-554e-8535-a49168c8bf4a","slug":"definition","fullItemName":"Definition"},{"id":"68cfd9ca-f6d9-582b-a898-39bd0927455f","slug":"categorization-of-adrs","fullItemName":"Categorization of ADRs"},{"id":"2bf3267e-f0ed-5301-b659-3a0d290262bc","slug":"health-financial-implications-of-adrs","fullItemName":"Health and financial implications of ADRs"},{"id":"804b9155-4dc6-574d-b5b3-3e320dd07967","slug":"monitoring-adverse-drug-reactions","fullItemName":"Monitoring adverse drug reactions"}]},{"id":"753ee7eb-1c21-5cf5-8e2e-e0e3ebd8be4a","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d7dbb3f-b730-5e84-aea1-49ed9234a126","slug":"adverse-drug-reactions","fullItemName":"Scenario: Adverse drug reactions"}]},{"id":"95500d82-4a44-5f81-befc-15cfb88abd53","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"77a8b838-04cb-5545-affe-c92faa19e1bb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"dfa6f9b0-4f82-5b25-99fb-5ce802d731e8","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f85a17d1-c7b8-5ebf-a80c-88c2f6c69eff","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5aee896a-ac4b-5a54-bde2-0577412d6418","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"8054ea0e-276d-5167-818e-fec1d38114aa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1a62db49-0d92-514d-9a4a-dfa05227ec25","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"86d8d508-d776-5c0a-be24-6df70fb79006","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b68bacaa-d4b5-58a7-b9d6-46bf7c82f8ad","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}